Teva Pharmaceutical Non-GAAP EPS of $0.66 beats by $0.04, revenue of $4.18B misses by $90M

6 days ago 2

Teva Pharmaceutical press release (NYSE:TEVA): Q2 Non-GAAP EPS of $0.66 beats by $0.04.
Revenue of $4.18B (+0.5% Y/Y) misses by $90M.
Increase of 2025 key innovative products revenues and EPS outlook and reaffirms all other outlook components:
- Revenues of $16.8 ‐ $17.2 billion (reaffirmed) vs consensus

Recommended For You